烧伤患者对头孢他啶-阿维巴坦耐药病例报告
本文报告一例54岁、58%总体表面积热烧伤患者,因多次假单胞菌感染接受多疗程抗生素治疗。后续耐药假单胞菌肺炎使用头孢他啶-阿维巴坦2.5g每6小时治疗,患者改善7天后再次发热且白细胞升高,血培养显示对头孢他啶-阿维巴坦MIC为16 mcg/mL的多重耐药假单胞菌,高于CLSI折点8 mcg/mL。遗传学检测显示存在多种编码β-内酰胺酶的基因。
要点
- 烧伤患者因药代动力学改变和多重耐药菌风险,抗感染治疗失败风险高。
- 头孢他啶-阿维巴坦治疗期间可出现耐药,需警惕发热和白细胞升高。
- 耐药可能源于多种β-内酰胺酶基因,而非单纯剂量不足。
核心结论
- 烧伤患者使用头孢他啶-阿维巴坦治疗假单胞菌感染期间可能发生耐药,且耐药与多种β-内酰胺酶基因相关。
研究设计与样本
- 病例报告,对象为一名54岁、58% TBSA热烧伤患者。
主要发现
- 初始假单胞菌创面感染对头孢吡肟、氨基糖苷类和美罗培南敏感。
- 后续耐药假单胞菌肺炎因头孢吡肟MIC 16 mcg/mL、美罗培南MIC >8 mcg/mL,使用头孢他啶-阿维巴坦2.5 g每6小时治疗。
- 治疗7天改善后患者再次发热、白细胞升高,血培养示多重耐药假单胞菌对头孢他啶-阿维巴坦MIC 16 mcg/mL,高于CLSI折点8 mcg/mL。
- 遗传学检测显示存在多种编码β-内酰胺酶的基因。
临床怎么用
- 烧伤患者使用新型抗生素治疗多重耐药菌感染时,应警惕治疗期间耐药的发生。
- 对β-内酰胺类治疗反应不佳时,需考虑耐药机制检测而非仅调整剂量。
局限性
- 为单例病例报告,结论外推受限。
- β-内酰胺类治疗药物监测在多数机构不可行。
- 耐药基因检测需要专门设施,且现有技术不能覆盖所有耐药标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burn patients have numerous risk factors for multidrug-resistant organisms (MDROs) and altered pharmacokinetics, which both independently increase the risk of treatment failure. Data on appropriate antimicrobial dosing are limited in this population and therapeutic drug monitoring (TDM) for beta-lactams is impractical at most facilities. Technology is available that can detect genetic markers of resistance, but they are not all encompassing, and often require specialized facilities that can detect less common genetic markers. Newer antimicrobials can help combat MDROs, but additional resistance patterns may evolve during treatment. Considering drug shortages and antimicrobial formularies, clinicians must remain vigilant when treating infections. This case report describes the development of resistance to ceftazidime-avibactam in a burn patient. The patient was a 54-year-old burn victim with a 58% total body surface area (TBSA) thermal burn who underwent multiple courses of antibiotics for various Pseudomonal infections. The initial Pseudomonal wound infection was sensitive to cefepime, aminoglycosides, and meropenem. A subsequent resistant pseudomonal pneumonia was treated with ceftazidime-avibactam 2.5 g every 6 hours due to the elevated MIC to cefepime (16 mcg/mL) and meropenem (>8 mcg/mL). Although the patient improved over 7 days, the patient again spiked fevers and had increased white blood counts (WBC). Repeat blood cultures demonstrated a multidrug-resistant (MDR) Pseudomonas with a minimum inhibitory concentration (MIC) to ceftazidime-avibactam of 16 mcg/mL, which is above the Clinical and Laboratory Standards Institute (CLSI) breakpoint of 8 mcg/mL. At first, resistance was thought to have occurred due to inadequate dosing, but genetic work demonstrated multiple genes encoding beta-lactamases.
引用
- Herbin SR, Barber KE, Isaacson AR, et al. When More Is Still Not Enough: A Case of Ceftazidime-Avibactam Resistance in a Burn Patient. J Burn Care Res. 2022. PMID: 34427655. doi:10.1093/jbcr/irab160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。